VC Deals Analysis: 2016 Bucks The Trend As Investment Dollars Dip
2016 was the year to break the bull run in venture investment activity, with total deal value and volume failing to surpass that of 2015. However, the IVD sector continued to be the most popular area for investment, and technologies that can help unravel the genomic puzzle behind diseases like cancer were the ones that attracted the big bucks last year and look likely to remain so in 2017.
You may also be interested in...
Market Intel: Nanorobots, Digital Tracking, Dose Printing: Innovative Drug Delivery Systems Will Make Precise Drug Dosing A Reality
Precision medicine delivered by novel drug delivery systems, ranging from sensors to dose printers, could eventually revolutionize the pharmaceutical industry. Although many of these technologies are years away from commercialization, their ability to provide exact dosing with slow sustained release and more targeted therapy should improve patient compliance and outcomes.
The last month of 2016 saw a final flurry of medtech M&A activity as companies rushed to seal deals before the New Year arrived. Medtech Insight's M&A data tracker recorded twice as many deals in December compared to the previous month, but that was not enough to boost the year's tally, which fell behind 2015.
The flow of VC deals continued to hold steady in April, with 22 transactions of $1m and over recorded last month and over $626m raised in total.